The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2024 | SRI results from MajesTEC-4: Tec-Len or Tec alone as maintenance therapy in newly diagnosed myeloma
Elena Zamagni, MD, PhD, University of Bologna, Bologna, Italy, discusses the results of the safety run-in (SRI) portion of the MajesTEC-4 trial (NCT05243797), a study evaluating the use of teclistamab (Tec) alone or in combination with lenalidomide (Len) as maintenance therapy following autologous stem cell transplantation (autoSCT) in newly diagnosed transplant-eligible multiple myeloma (MM). Dr Zamagni highlights the impressive efficacy of teclistamab, with all patients achieving measurable residual disease (MRD) negativity and almost all achieving complete remission (CR), but also emphasizes the increased infection risk that must be anticipated and managed appropriately. This interview took place at the 66th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript (AI-generated)
That’s the first study testing the use of teclistamab as maintenance therapy in newly diagnosed transplant-eligible multiple myeloma following autologous stem cell transplantation. So at ASH 2024 we presented the initial results of the safety run-in portion of the study, which tested the combination of Tec-len and also Tec alone.
So what we showed are two things mainly, the efficacy is huge – among all the tested patients all of them are reaching MRD negativity and almost all of them are reaching CR...
That’s the first study testing the use of teclistamab as maintenance therapy in newly diagnosed transplant-eligible multiple myeloma following autologous stem cell transplantation. So at ASH 2024 we presented the initial results of the safety run-in portion of the study, which tested the combination of Tec-len and also Tec alone.
So what we showed are two things mainly, the efficacy is huge – among all the tested patients all of them are reaching MRD negativity and almost all of them are reaching CR. So this is the first part. The second part is that even in a newly diagnosed transplant-eligible myeloma population, so less pre-treated, the younger, the infection signal is there. So we have to take care and to be careful about this. Approximately 30% of the patients got grade 3 or 4 infection, mostly upper respiratory tract infections that could be managed. So the good news is that we can take care of this, and manage it. So absolutely, immunoglobulin replacement is highly recommended and antibiotic prophylaxis as well. So those are mainly the two messages. Now the Phase III portion of the study is already open and actively recruiting. So that’s a huge study, 500 patients across the whole globe. So we will see what the final results will be.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
Disclosures
Bristol Myers Squibb: Honoraria, Membership on an entity’s Board of Directors or advisory committees; Pfizer: Honoraria, Membership on an entity’s Board of Directors or advisory committees; Janssen: Honoraria, Membership on an entity’s Board of Directors or advisory committees; Menarini Stemline: Honoraria, Membership on an entity’s Board of Directors or advisory committees; Amgen: Honoraria, Membership on an entity’s Board of Directors or advisory committees; Sanofi: Honoraria, Membership on an entity’s Board of Directors or advisory committees; Oncopeptides: Honoraria, Membership on an entity’s Board of Directors or advisory committees.
